Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Polomar Health Services's Business Segments
Polomar Health Services's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Prescription Fulfillment
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Prescription Fulfillment0%
- Others0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Prescription Fulfillment | $ 3 | - |
| Others | - | 0% |
Revenue by Product & Service Category - FY
- Prescription Fulfillment0%
- Others0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Prescription Fulfillment | $ 2 | - |
| Others | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Prescription Fulfillment0%
- Others0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Prescription Fulfillment | $ 3 | - |
| Others | - | 0% |
Description of Polomar Health Services
Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, LLC, a licensed retail compounding pharmacy located in Palm Harbor, Florida. The pharmacy holds a Special Sterile Compounding Pharmacy permit, authorizing it to dispense injectable and other sterile compounded medications upon valid prescriptions. Operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, Polomar Specialty Pharmacy manufactures compounded drugs and fulfills prescriptions from licensed healthcare professionals. It is authorized to deliver compounded medications in 28 states and is pursuing additional state licenses to expand its distribution by mid-2026. Prior to merging with Polomar Specialty Pharmacy on September 30, 2024, the business specialized in compounded dermatological prescription medications for topical use, co-developed with a board-certified dermatologist to treat various skin conditions. In 2024, the pharmacy expanded its capabilities by constructing clean rooms and obtaining a Special Sterile Compounding Permit, enabling it to dispense sterile compounded drugs, including GLP-1 agonists for subcutaneous injection. In 2025, Polomar entered a pharmacy services agreement with CareValidate, Inc. to fulfill GLP-1 agonist prescriptions for CareValidate's online clinics. Despite these developments, Polomar Specialty Pharmacy has experienced significant operational losses due to declining revenues and increased labor costs.